HARP - Harpoon Therapeutics to Host KOL Event in Person and via Webcast on September 15 2023 | Benzinga
KOLs to provide insight and discussion of HPN328 targeting SCLC, NEPC and other neuroendocrine tumors
Abstract with HPN328 interim data accepted for poster presentation at the European Society for Medical Oncology (ESMO) being held October 20-24, 2023
SOUTH SAN FRANCISCO, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ:HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced that management will host an in-person event "DLL3 Market Opportunity and KOL Discussion of HPN328", in New York on September 15, 2023 from 8:00 to 9:30 a.m. ET. Invited key opinion leaders (KOLs) will discuss HPN328, a DLL3-targeting tri-specific T cell engager, and its potential in the treatment of small cell lung cancer (SCLC), NEPC (neuroendocrine prostate cancer) and other neuroendocrine carcinomas. The agenda will also include a management overview of the market potential for selected DLL3 expressing tumor types and an update on Harpoon's clinical development pipeline, including upcoming milestones.
KOL Guest Speakers
- Himisha Beltran, M.D., Associate Professor, Medical Oncology, Dana-Faber Cancer Institute, Harvard Medical School
- Erin Schenk, M.D., Ph.D., Assistant Professor of Medicine, Division of Medical Oncology, University of Colorado Anschutz Medical Campus
Registration Information ...